These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL; Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011 [TBL] [Abstract][Full Text] [Related]
11. Retrospective case review of pediatric patients with uveitis treated with infliximab. Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545 [TBL] [Abstract][Full Text] [Related]
12. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077 [TBL] [Abstract][Full Text] [Related]
14. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602 [TBL] [Abstract][Full Text] [Related]
17. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830 [TBL] [Abstract][Full Text] [Related]
18. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Walton RC; Nussenblatt RB; Whitcup SM Ophthalmology; 1998 Nov; 105(11):2028-34. PubMed ID: 9818601 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466 [TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]